Comparing the current results to its competitors, Liquidia reported Revenue increase in the 2 quarter 2026 by 1842.73 % year on year. The sales growth was above Liquidia's competitors' average revenue growth of 4.25 %, achieved in the same quarter.
Liquidia's Comment on Competition and Industry Peers
The company operates in a highly competitive and rapidly evolving pharmaceutical industry focused on proprietary products. Its competitors include major multinational pharmaceutical firms, established biotechnology and biopharmaceutical companies, and generic drug manufacturers. Many competitors possess greater financial resources, larger research and development teams, and more extensive marketing and manufacturing capabilities, which may enable them to obtain marketing approvals more quickly and market products more effectively. Smaller or early-stage companies can also be significant competitors, particularly through collaborations with larger, established firms. The company's product candidates compete with existing and future therapies based on factors such as efficacy, safety, convenience, price, and reimbursement availability. Competitors may develop or acquire more effective or less costly technologies and drug products, potentially rendering the company's products obsolete or less competitive.
October 2, 2024
Advancements in Inhaled Therapies: Liquidia and Pharmosa Biopharm Strengthen Collaboration on Sustained Release Treprostinil Innovative pharmaceutical solutions continue to evolve as global health challenges demand more effective and sustained treatments. In an effort to address the pressing needs in pulmonary arterial hypertension (PAH) management, Liquidia Corporation and Pharmosa Biopharm have announced an amendment to their exclusive licensing agreement. This development marks a new phase in their collaborative endeavor to advance the commercialization of L606, a sustained release inhaled formulation of treprostinil. Enhancing Treprostinil Delivery for PAH Patients Pulmonary Arterial Hypertension is a pr...
January 8, 2024
In a recent development in the pharmaceutical industry, Liquidia Corporation (NASDAQ: LQDA) has filed its response and counterclaims against United Therapeutics Corporation (UTHR). This legal battle revolves around alleged patent infringement regarding Liquidia s New Drug Application (NDA) for YUTREPIA (treprostinil) inhalation powder. The filing also sheds light on several omitted publications, references, and information during the patent prosecution process. Liquidia s move highlights potential oversights by the United States Patent and Trademark Office (USPTO).The amended complaint by UTHR, filed on November 30, 2023, invoked the Drug Price Competition and Patent Term Restoration Act (commonly known as t...
Hoth Therapeutics Inc's business model focuses on the development and commercialization of innovative therapies for dermatological disorders and other related conditions.
Theravance Biopharma Inc's business model focuses on developing and commercializing innovative therapeutics to address unmet medical needs in various therapeutic areas.
Pulmatrix Inc is a biopharmaceutical company that focuses on developing and commercializing innovative inhaled therapies for respiratory diseases. Their business model revolves around creating novel inhaled drug delivery technologies and collaborating with partners to advance their product pipeline, aiming to provide effective treatments for patients with respiratory conditions.
Sources:
Liquidia Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Liquidia Corporation versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
